Supriya Lifescience Ltd

SUPRIYA NSE Healthcare Pharmaceuticals
Microcap 250
₹901.75
-1.71%
Delayed · cached 15 min

Fair value analysis

SUPRIYA
Supriya Lifescience Ltd
Healthcare›Pharmaceuticals
₹917.45
Close used for this calculation
₹738.91Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
57/100
Profitability25/25
Returns10/25
Balance Sheet14/25
Efficiency8/25
Growth12/25
Good
Quality radar
57Prof.25/25Ret.10/25Eff.8/25B.Sht14/25Growth12/25

Consensus fair value

₹738.91
Above FV
▼ -19.5% against the close used
Model range ₹85.31 – ₹1,170.03
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹85.31Fair value₹738.91Bull₹1,170.03
FairClose
52-week traded range
52W low ₹553.3552W high ₹1,052.50

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Supriya Lifescience Ltd closed at ₹917.45, 24.2% above the consensus fair value of ₹738.91 drawn from 9 valuation models.

Financial DNA score 57/100 — Good. P/E of 36.5x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₹85.31
-90.7%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₹290.38
-68.3%
√(22.5 × EPS × BVPS)
EPS=25.98, BVPS=144.25 · outside Graham range (P/E 36.5, P/B 6.4) — asset-light, treat as a rough floor
Graham Formula
₹1,170.03
+27.5%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=20%, FD=7%
P/E Fair Value
₹927.49
+1.1%
EPS × 35.7x (sector P/E)
EPS=25.98, Sector P/E=35.7x
Peter Lynch (PEG)
₹649.50
-29.2%
EPS × Growth% (PEG = 1 is fair)
EPS=25.98, g=25%
EV/EBITDA
₹734.29
-20.0%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=3.23B
Book Value (P/B)
₹472.43
-48.5%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=144.25, ROE=19.1%, g=6%, r=10%
Reverse DCF
₹917.45
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 14.8% | Historical: 25%
Margin of Safety
₹463.73
-49.5%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=618.3, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.